https://doi.org/10.55788/0390b754
Recurrent wheezing and asthma often occur after severe RSV bronchiolitis [1]. Aiming to solve this clinical problem, Prof. Avraham Beigelman (Schneider Children's Medical Center of Israel, Israel) and co-investigators developed a randomised trial to analyse whether azithromycin outperformed placebo with respect to recurrent wheezing in hospitalised patients with RSV bronchiolitis (n=200; 1–18 months of age). The primary results did not demonstrate a difference between placebo and azithromycin on recurrent wheezing after an RSV infection [2]. Prof. Beigelman presented the results of a post-hoc analysis of this trial, investigating the influence of non-macrolide antibiotics on the effect of azithromycin on recurrent wheezing [3].
In participants receiving other antibiotics next to azithromycin (30%), there was no difference in the risk for recurrent wheezing between the azithromycin arm and the placebo arm (HR 0.94; 95% CI 0.43–2.07; P=0.88). In contrast, in the no-other-antibiotic-stratum, participants receiving placebo performed better than participants receiving azithromycin (HR 1.79; 95% CI 1.03–3.1; P=0.037). In fact, the study showed that the use of any antibiotic may increase the risk of recurrent wheezing compared with placebo (HR 1.65; 95% CI 1.00–2.72; P=0.048).
“These results indicate that azithromycin, and likely other antibiotic agents, should be avoided during early-life, severe, RSV bronchiolitis,” emphasised Prof. Beigelman. “In our next project, we will investigate whether the harmful effect of antibiotics is due to the impact these medications have on the gut microbiome.”
- Bacharier LB, et al. J Allergy Clin Immunol. 2012;130(1):91–100.e3.
- Beigelman A, et al. NEJM Evid. 2022;1(4).
- Beigelman A, et al. Antibiotic use during severe RSV bronchiolitis may increase subsequent recurrent wheeze risk. ALERT 2, RCT2164, ERS International Congress 2022, Barcelona, Spain, 4–6 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Inhaled corticosteroids useful in preterms with decreased lung function Next Article
Confirmatory mediastinoscopy not needed in resectable NSCLC »
« Inhaled corticosteroids useful in preterms with decreased lung function Next Article
Confirmatory mediastinoscopy not needed in resectable NSCLC »
Table of Contents: ERS 2022
Featured articles
Letter from the Editor
COVID-19: What Is New?
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COPD: Therapies and Innovations
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
All About Asthma
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Progress in Paediatrics
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Inhaled corticosteroids useful in preterms with decreased lung function
Fish oil or vitamin D during pregnancy can prevent croup
Encouraging results of nintedanib in children with fibrosing ILD
Focus on Interventional Pulmonology
Head-to-head: lung volume reduction surgery vs endobronchial valves
Durable effect of endobronchial valves in severe emphysema
Cone beam CT-guided ENB improves detection of pulmonary nodules
Confirmatory mediastinoscopy not needed in resectable NSCLC
Sleep and Breathing Disorders
In the spotlight: Cancer trends in obstructive sleep apnoea
Impact of CPAP on cardiac endpoints in OSA
Sustained hypoxaemia predicts unprovoked VTE in OSA
CPAP therapy in the prevention of cardiovascular risk in patients with OSA
Other Remarkable Research
Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure
Antifibrotic therapy may slow down FVC decline in RAILD
Intravenous N-acetylcysteine performs well in hospitalised patients
Men and women respond differently to diesel exhaust
New trends in cystic lung diseases
Related Articles
November 28, 2019
Taxi drivers exposed to highest levels of black carbon pollution
November 4, 2024
Relatlimab addition benefits only a subgroup of metastatic NSCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com